RxDoctor Payments Data

Amir Masoud, MD

Gastroenterology · New Haven, CTNPI 1083878821

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,105 of the $26,445 with a category attached, or 94.9%. Covidien LP accounts for 94.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $12,844 and has fallen 99.6% since, to $57 in 2024.

$26,445in general payments, 2019–2025

Across 20 payments — averaging $1322.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$25K
  • Medtronic$1K
  • Endogastric Solutions, Inc$99
  • AbbVie$86
  • Dentsply IH AB$57
  • Laborie Medical Technologies Corp.$19
$26,004in research payments, 2019–2025

Across 18 payments — averaging $1444.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ironwood Pharmaceuticals, Inc$26K

What the payments were for

  • Speaking & faculty fees$25,10595%
  • Travel & lodging$9634%
  • Food & beverage$3771%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,445 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$60,890
Medicare patients
199
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MotegrityPrucalopride Succinate48$47,629
GimotiMetoclopramide Hcl14$29,693
LinzessLinaclotide22$29,645
MovantikNaloxegol Oxalate36$22,055
Esomeprazole Magnesium30$1,473
Cyproheptadine Hcl87$1,367
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates21$1,226
Colestipol Hcl14$1,084
Famotidine34$598
Omeprazole25$557
Azithromycin52$553
Amitriptyline Hcl14$206
Ondansetron OdtOndansetron11$96
Lactulose12$94
Baclofen12$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$86$29,64522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →